Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders

Am J Hematol. 2005 Jul;79(3):211-5. doi: 10.1002/ajh.20334.

Abstract

Post-transplant lymphoproliferative disorder (PTLD) represents a spectrum of lymphoid proliferative diseases seen as result of immunosuppression in recipients of solid organ or hematopoietic stem-cell transplantation. Options of treatment include reduction or discontinuation of immunosuppressive agents, antiviral drugs, rituximab, chemotherapy, and radiation. We report two unique cases of PTLD (CNS and plasmacytoma-like) treated successfully with salvage chemotherapy, mini-BEAM chemotherapy, and autologous stem-cell transplant. In both cases, patients were also treated with sirolimus and prednisone as immunosuppression, and neither patient rejected their solid organ transplants. With over 30 months of follow-up, both patients remain in complete remission with excellent allograft function.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carmustine / therapeutic use
  • Cytarabine / therapeutic use
  • Etoposide / therapeutic use
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / therapy*
  • Male
  • Melphalan / therapeutic use
  • Middle Aged
  • Salvage Therapy
  • Transplantation, Autologous
  • Transplants / adverse effects*

Substances

  • Cytarabine
  • Etoposide
  • Melphalan
  • Carmustine

Supplementary concepts

  • BEAM regimen